Product Name	Elagolix Sodium
CAS No.	832720-36-2
Content	99%+
Structural formula

The products listed by the company involve patents and are only for research and development, not for sale; the controlled products will be sold in strict compliance with Chinese laws and the laws of the purchasing country, and all products are not suitable for human use. If they are sold to the country constituting patent infringement, the corresponding risks will be borne by the buyer.

Advantages of Elagolix Sodium:



(1) Change from injection medication to oral medication



(2) The medication has been used for a long time before



(3) The original large clinic has not yet entered China



(4) The compound patent will expire in the year 2024,                     means the patent time is short.



Endometriosis is a common disease in women, affecting 10% women of childbearing age.

For women of different ages, two clinical trials have shown that Elagolix dose-dependently reduces dysmenorrhea or non-menstrual pelvic pain in patients with endometriosis, because this product is bone density is less affected, combined with the advantages of oral administration, this product is expected to become a major pound bomb.

Clarivate Analytics predicts that sales of this product will reach 2.0 billion dollars by the year 2024.

Product Name
CAS No.
Your Name	*
Your Company
Country
Add
Tel	*
Fax
E-Mail	*
Your Demand
Verification Code